

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

DOES IT MAKE SENSE TO DEVELOP NEW CENTRALLY ACTING CARDIOVASCULAR DRUGS?

P Bousquet, L Monassier and J Feldman

Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Université Louis Pasteur, Faculté de Médecine, Strasbourg, France

SUMMARY

1. The autonomic nervous system plays a pivotal role in modulating all the components of the cardiovascular regulation. Therefore, one can assume that drugs targeting this system may be useful in the management of several cardiovascular diseases.

2. Drugs acting on central nervous system centres seem to be modulators rather than blockers; as such, they are expected to preserve the contraregulatory processes and to generate only a few side effects.

3. Because the sympathetic nervous system is largely involved in the regulation of vasomotor tone, centrally acting anti-hypertensive drugs were developed first.

4. Recently, new leader compounds selective for non-adrenergic imidazoline receptors have been synthesized. Although such drugs have no capacity to activate α_2 -adrenoceptors, they have been proven to be hypotensive. These drugs are expected to be even better tolerated than the currently available centrally active drugs. They may also have additional beneficial effects.

5. Here, the experimental evidence suggesting that such drugs may be useful in the management of some cardiac arrhythmias and/or left ventricular dysfunction will be reviewed.

Key words: autonomic nervous system, cardiac arrhythmias, congestive heart failure, hypertension, imidazolines.

INTRODUCTION

Interest in the autonomic nervous system (ANS) as a target for cardiovascular drugs has recently been strengthened for several reasons. Not only has a second-generation class of centrally acting antihypertensive drugs efficient as first-line well-tolerated drugs been introduced (e.g. rilmenidine and moxonidine),¹ but also several indices related to ANS activity have been shown^{2,3} to predict the prognosis of some cardiovascular diseases. Thus, plasma noradrenaline levels are correlated with the severity of congestive heart failure (CHF) and variabilities in blood pressure and heart rate,

which depend to a great extent on ANS activity, are often proposed as cardiovascular morbidity and/or mortality predictors.^{4,5} Recently, beta-blocking drugs have been introduced for the management of heart failure, despite the fact that they have been contraindicated in this field for at least three decades. Increasing interest is now directed towards the metabolic syndrome that associates hypertension, sympathetic hyperactivity and hyperinsulinaemia, in particular to the sympathetic component of this syndrome. Finally, very recently new leader compounds that act centrally but on original pharmacological targets have become available.^{6,7}

The present review will summarize some of the arguments supporting the contention that drugs acting within sympathetic centres may be of interest for the management not only of hypertension but also cardiac arrhythmias and CHF. In fact, these pathologies are often interwoven through a sympathetic hyperactivity. In these cases, well-tolerated centrally acting sympathoinhibitors would be of major interest. So far, only a few studies have been undertaken to assess the potential of such drugs in this metabolic syndrome and myocardial ischaemia; that is why these pathologies will be omitted in the present review.

TOWARDS A THIRD GENERATION OF CENTRALLY ANTIHYPERTENSIVE DRUGS?

A long time ago, we demonstrated that, compared with α -methyl noradrenaline, the active metabolite of α -methyl dihydroxyphenylalanine (DOPA), imidazoline compounds, such as clonidine, have a different site of action within the brainstem.⁸ These drugs also have a different mechanism of action.⁹ Recently, we reported new evidence for these differences. Pretreatment with nitro-L-arginine given centrally completely abolished the hypotensive effect of α -methyl noradrenaline. In contrast, inhibition of nitric oxide synthase had no effect on the clonidine-induced decrease in blood pressure.¹⁰ Nitric oxide (NO) is required for the release process of several neurotransmitters within the central nervous system. A GABAergic pathway coming from the nucleus tractus solitarius (NTS) projects to the nucleus reticularis of the rostroventrolateral part of the medulla. Therefore, our data are consistent with the view that α -methyl noradrenaline, which is known to stimulate α_2 -adrenoceptors of the NTS, stimulates this pathway and activates NO-dependent GABA release within the nucleus reticularis area. Finally, GABA will inhibit the so-called cardiovascular sympathetic neurons in this particular nucleus. Because clonidine and related compounds inhibit these neurons by acting directly within the nucleus reticularis, they do not need NO. The latter action is mediated by non-adrenoceptors called imidazoline receptors, whereas the side effects of the clonidine-like drugs were clearly attributed to

Correspondence: P Bousquet, Laboratoire de Neurobiologie et Pharmacologie, Cardiovasculaire, Université Louis Pasteur, Faculté de Médecine, 11 rue Humann, 67000 Strasbourg, France.
Email: Pascal.Bousquet@medecine.u-strasbg.fr

Presented at the IIIrd Franco-Australian Meeting on Hypertension, Corsica, France, June 2001. The papers in these proceedings have been peer reviewed.

Received 14 July 2001; accepted 26 July 2001.

their remaining capacity to stimulate α_2 -adrenoceptors.¹ Therefore, considerable efforts were made to synthesize compounds selective for these non-adrenoceptors. Very recently, a series of such drugs became available. We described that two representatives of these kinds of drugs, namely LNP 509 and S23515, with no detectable affinity for and no activity at α_2 -adrenoceptors, were able to decrease blood pressure when delivered centrally.^{6,7} At the present time, compounds LNP 509 and S23515 are the leaders in the development of a third generation of centrally acting antihypertensive drugs. Preliminary animal experiments (P Bousquet *et al.*, unpubl. obs., 2001) have shown that, as expected, these drugs have no sedative effects at hypotensive doses.

CENTRAL ANTI-ARRHYTHMIC EFFECTS

Rilmenidine is an oxazoline, that is, an analogue of imidazoline compounds such as clonidine. Rilmenidine has proved useful in treating mild to moderate hypertension, with an acceptability similar to that of more recent classes of antihypertensive drugs (e.g. angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists) or to that of a placebo.¹ One of the risks associated with hypertensive diseases is that of ventricular arrhythmias, which are observed in approximately 30% of patients. These arrhythmias usually occur in patients with left ventricular hypertrophy. They may result in sudden death.¹¹⁻¹⁴

In rabbits, arrhythmias of central origin associated with sympathetic hyperactivity were induced by central (intracisternal) injection of the GABA_A receptor antagonist bicuculline. In this model, rilmenidine reduces the occurrence of ventricular arrhythmias in a dose-dependent manner.¹⁵ Bicuculline, delivered intracisternally, evoked a marked hypertensive response accompanied by ventricular ectopic beats, episodes of ventricular tachycardia evolving into a sustained tachycardia and, finally, fibrillation, which is fatal in the absence of treatment. Pretreatment of these animals with cumulative doses (10 μ g/kg to 1 mg/kg) of intravenous rilmenidine significantly prevented the occurrence of all bicuculline-induced arrhythmic events in a dose-dependent manner.¹⁵ Rilmenidine given intracisternally (10–30 μ g/kg) had very similar cardioprotective effects. It is interesting to note that, in this experimental model, rilmenidine had anti-arrhythmic effects even at doses lower than those needed to decrease blood pressure.¹⁵ In addition, treatment with idazoxan, a selective imidazoline antagonist, confirmed that the anti-arrhythmic effect of rilmenidine involves imidazoline-specific receptors.¹⁵ Our results were consistent with those of Mammoto *et al.*, who have reported that rilmenidine prevents the occurrence of ventricular arrhythmias induced by a mixture of halothane and adrenaline.¹⁶

Thus, centrally acting drugs are potentially useful as anti-arrhythmics even at doses devoid of any hypotensive action.

Very recently, drugs selective for imidazoline receptors over α_2 -adrenoceptors were synthesized in our laboratory.⁷ For instance, preliminary data show that LNP 509 has no action at α_2 -adrenoceptors but that it does have a remarkable preventing effect against bicuculline-induced ventricular arrhythmias in rabbits (J Feldman *et al.*, unpubl. obs., 2001).

Thus, a novel class of centrally acting anti-arrhythmic drugs takes shape. Because, according to the results of the Cardiac Arrhythmias Suppression Trial (CAST) study,^{17,18} most available anti-arrhythmic drugs are of restricted use given their adverse effects (in particular

their paradoxical pro-arrhythmic actions), a new class of anti-arrhythmic drugs devoid of such side effects would be extremely valuable.

LEFT VENTRICULAR DYSFUNCTION: CONGESTIVE HEART FAILURE

An interesting debate has been going on regarding the treatment of CHF. We tackled this subject keeping in mind the observation that sympathetic activation is associated with severe left ventricular failure. Although this sympathetic hyperactivity is a compensatory process, it also accelerates the progression of the disease and increases the morbidity and mortality due to CHF. Plasma levels of noradrenaline are a predictive index of the evolution of the disease.¹⁹ The overall result of the alterations associated with CHF²⁰ is, in fact, an elevation of systemic vascular resistance, this being still further aggravated by activation of the renin-angiotensin-aldosterone system as a result of sympathetic stimulation. As far as left ventricular ejection fraction (LVEF) is concerned, this functional cascade is critical.

All drugs available that are used to treat CHF have their own restrictions.²⁰⁻²²

The potential interest of centrally acting drugs in the treatment of CHF is quite obvious. Drugs that specifically inhibit sympathetic activity would reduce the release of noradrenaline and adrenaline from the adrenal glands and, as a result, would diminish systemic vascular resistance and prevent activation of the renin-angiotensin-aldosterone system. All these effects would improve diastolic function and restore LVEF.²³ In addition, centrally acting drugs that not only inhibit sympathetic activity but also facilitate vagal activity would contribute to normalizing heart rate variability. There are already clinical data obtained for clonidine and α -methyl DOPA confirming the potential interest of centrally acting drugs in the treatment of heart failure.²⁴⁻²⁷

In Goldblatt hypertensive rats (one kidney, one clip), clonidine, for example, not only improves the life span and haemodynamic features of the rats, but it also has a promising anti-apoptotic effect in the myocardium (L Thomas *et al.*, unpubl. obs., 2001). The second generation of centrally acting sympathoinhibitory drugs has few side effects. For example, these drugs have neither negative inotropic effects, at least at reasonable doses, nor do they affect lipid and glucose metabolism.¹ Whether such drugs may be useful in the treatment of CHF at non-hypotensive doses remains to be demonstrated. Moreover, selective drugs, such as LNP 509, will be tested, of course, in CHF models.

CONCLUSIONS

The additional cardioprotective effects (anti-arrhythmic and prevention of left ventricular dysfunction) of second-generation centrally acting antihypertensive drugs should not be passed over in the further development of this new class of drugs.


The additional beneficial effects controlling risk factors associated with hypertension should boost the development of new centrally acting antihypertensive drugs. Henceforth, imidazoline-like drugs that do not act at α_2 -adrenoceptors at all are leader compounds in the development of well-tolerated new antihypertensive agents. Interest in this class of drugs will be improved further when clinical

trials have confirmed that these drugs may have cardioprotective actions in patients.

Finally, because the anti-arrhythmic effects and improvement in LVEF induced by these sympathoinhibitory drugs are observed even when blood pressure is not altered, we can assume that centrally cardioprotective but non-hypotensive substances will be developed as drugs in the near future.

REFERENCES

1. Bousquet P, Feldman J. Drugs acting on imidazoline receptors: A review of their pharmacology. *Drugs* 1999; 58: 799-812.
2. Brook RD, Julius S. Autonomic imbalance, hypertension and cardiovascular risk. *Am. J. Hypertens.* 2000; 13: S112-22.
3. Palatini P, Julius S. Relevance of heart rate as a risk factor in hypertension. *Curr. Hypertens. Rep.* 1999; 3: 219-24.
4. White CM. Catecholamines and their blockade in congestive heart failure. *Am. J. Health Syst. Pharm.* 1998; 55: 676-82.
5. La Rovere MT, Bigger Jr JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998; 351: 478-84.
6. Bruban V, Feldman J, Gency H et al. Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline like drugs. *Br. J. Pharmacol.* 2001; 133: 261-6.
7. Shann S, Bruban V, Pompenmayer K et al. Synthesis and biological evaluation of pyrrolidine isosters of rilmenidine. *J. Med. Chem.* 2001; 44: 1588-93.
8. Bousquet P, Feldman J, Bloch R, Schwartz J. The nucleus reticularis lateralis: A region highly sensitive to clonidine. *Eur. J. Pharmacol.* 1981; 69: 389-92.
9. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: Differences between catecholamines and imidazolines. *J. Pharmacol. Exp. Ther.* 1984; 230: 232-6.
10. Sy GY, Bruban V, Bousquet P, Feldman J. Nitric oxide and central anti-hypertensive drugs: One more difference between catecholamine and imidazolines. *Hypertension* 2001; 37: 246-9.
11. Molderings GJ. Imidazoline receptors: Basic knowledge, recent advances and future prospects for therapy and diagnostic. *Drug Future* 1997; 22: 757-72.
12. Bousquet P. Recent advances in imidazoline receptor research. *Exp. Opin. Invest. Drugs* 1995; 4: 431-42.
13. MacKaigie JP, Harron DWG. The effects of rilmenidine on tests of the autonomic function in humans. *Clin. Pharmacol. Ther.* 1992; 52: 511-17.
14. Harron DWG. Antihypertensive drugs and baroreflex sensitivity effect of rilmenidine. *Am. J. Med.* 1989; 87 (Suppl. 3C): S57-62.
15. Roegel JC, Yannoulis N, De Jong W, Monassier L, Feldman J, Bousquet P. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan in rabbits. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 1996; 354: 598-605.
16. Mammoto T, Kamibayashi T, Hayashi Y, Yamatodani A, Takada K, Yoshiya I. Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anesthetized dogs. *Br. J. Pharmacol.* 1996; 117: 1744-8.
17. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N. Engl. J. Med.* 1989; 321: 406-12.
18. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators. Effect of the antiarrhythmic agent monicizine on survival after myocardial infarction. *N. Engl. J. Med.* 1992; 327: 227-33.
19. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. *N. Engl. J. Med.* 1984; 311: 819-23.
20. Castellano M, Bohm M. The cardiac α -adrenoceptors-mediated signaling pathways and its alterations in hypertensive disease. *Hypertension* 1997; 29: 715-22.
21. Young SB. Clinical trials with implications regarding heart failure therapy. *Curr. Opin. Cardiol.* 1997; 12: 407-17.
22. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N. Engl. J. Med.* 1996; 334: 1349-55.
23. Manolis AJ, Olympios C, Sifaki M et al. Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. *Hypertension* 1997; 29: 525-30.
24. Giles TD, Iteld BJ, Mautner RK, Rognoni PA, Dillenkofer RL. Short-term effects of intravenous clonidine in congestive heart failure. *Clin. Pharmacol. Ther.* 1981; 30: 724-8.
25. Hermiller JB, Magorien RD, Leithe MB, Unverferth DV, Leier CV. Clonidine in congestive heart failure: A vasodilator with negative inotropic effects. *Am. J. Cardiol.* 1983; 51: 791-5.
26. Manolis AS, Varriale P, Nobile J. Short-term hemodynamic effects of intravenous methyl dopa in patients with congestive heart failure. *Pharmacotherapy* 1987; 7: 216-22.
27. Manolis AJ, Olympios C, Sifaki M et al. Suppressing sympathetic activation in congestive heart failure. *Hypertension* 1995; 26: 719-24.



Entrez PubMed Nucleotide Protein Genome Structure PMC Journals

Search PubMed for [] Limits Preview/Index History Clipboard Data

Text Version [15034] Abstract Show: 20 Sort [] Send to Text

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

1: Br J Pharmacol. 2001 May; 133(2): 261-6.

Related Article

Full text article at
www.brjpharmacol.org

Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.

Bruban V, Feldman J, Grenay H, Dontenwill M, Schann S, Jarry C, Payard M, Bo Scalbert E, Pfeiffer B, Renard P, Vanhoutte P, Bousquet P.


Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université Louis Pasteur, 11 rue Humann, 67000 Strasbourg, France.

The hypotensive effect of imidazoline-like drugs, such as clonidine, was first attributed exclusive stimulation of central alpha2-adrenoceptors (alpha2ARs). However, a body of evidence suggests that non-adrenergic mechanisms may also account for this hypotensive work aims (i) to check whether imidazoline-like drugs with no alpha2-adrenergic agonist activity may alter blood pressure (BP) and (ii) to seek a possible interaction between su and an alpha2ARs agonist alpha-methylnoradrenaline (alpha-MNA). We selected S235 S23757, two imidazoline-like drugs with negligible affinities and activities at alpha2AR with high affinities for non-adrenergic imidazoline binding sites (IBS). S23515 decreases dose-dependently (-27+/-5% maximal effect) when administered intracisternally (i.c.) to anaesthetized rabbits. The hypotension induced by S23515 (100 microg kg(-1) i.c.) was prevented by S23757 (1 mg kg(-1) i.c.) and efaroxan (10 microg kg(-1) i.c.), while these compounds, devoid of haemodynamic action by themselves, did not alter the hypotension of alpha-MNA (3 and 30 microg kg(-1) i.c.). Moreover, the alpha2ARs antagonist rauwolfia (3 microg kg(-1) i.c.) did not prevent the effect of S23515. Finally, whilst 3 microg kg(-1) S23515 or 0.5 microg kg(-1) of alpha-MNA had weak hypotensive effects, the sequential administration of these two drugs induced a marked hypotension (-23+/-2%). These results indicate that an imidazoline-like drug with no alpha2-adrenergic properties lowers BP and interacts synergistically with an alpha2ARs agonist.

PMID: 11350862 [PubMed - indexed for MEDLINE]

[15034] Abstract Show: 20 Sort [] Send to Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer



Entrez PubMed Nucleotide Protein Genome Structure PMC Journals

Search PubMed for [] Limits Preview/Index History Clipboard Data

About Entrez

Text Version

Abstract Show: 20 Sort [] [] Text

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

1: J Med Chem. 2003 May 22; 46(11): 2169-76.

Related Arti



Imidazoline binding sites (IBS) profile modulation: key role of the br determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues.

Gentili F, Bousquet P, Brasili L, Dontenwill M, Feldman J, Ghelfi F, Giannella M, Piergentili A, Quaglia W, Pigini M.

Dipartimento di Scienze Chimiche, Università degli Studi di Camerino, via S. Agostino Camerino, Italy.

The alpha- and beta-methyl derivatives of 2-phenylethylimidazoline (compounds 7 and the corresponding enantiomers were prepared and tested with the purpose of studying th played by the ethylene bridge in modulating I(1)- and I(2)-IBS selectivity. The alpha-methylation appeared to be extremely critical regarding the affinity and selectivity for t subtypes (I1/I2 = 186 for imidazoline 7) and the stereospecificity of interaction (eudism (S)-(-)-7/(R)-(+)-7 = 5888). Instead, even if in a more limited fashion, the -methylation toward I2-IBS selectivity (I2/I1 = 50 for imidazoline 8). The unsubstituted compound 4 1479) proved to be considerably more potent and selective with respect to I2-IBS subty

PMID: 12747788 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort [] [] Text

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Jan 14 2